bhi-updated-logo-2017

Are you an experienced biohealth entrepreneur seeking new opportunities in the BioHealth Capital Region? BioHealth Innovation is developing a database of experienced industry personnel willing to work in potential C-suite positions with our university and startup partners. If you would like to have your contact information and vita included in this database for their review, please email This email address is being protected from spambots. You need JavaScript enabled to view it. an updated vita by this Thursday, February 14th.

NewImage

YOU THOUGHT SHARK TANK WAS TOUGH?

NOW ACCEPTING APPLICATIONS at

https://form.jotform.com/90276838255163 

Submit your application for a chance to be named the Startup with the Most Commercial Potential at the BioHealth Capital Region Forum, win $10,000 and more!

APPLICATION DEADLINE: March 8, 2019

FINALISTS ANNOUNCED: March 21, 2019

PRESENT AT THE BIOHEALTH CAPITAL REGION FORUM APRIL 9, 2019PRESENT AT THE BIOHEALTH CAPITAL REGION FORUM APRIL 9, 2019

Finalists will have a chance to win the grand prize by presenting in front of a panel of prominent industry funding experts and executives.

Distinguished Judges:

  • Moderator - Rich Bendis, President and CEO, BioHealth Innovation
  • 2019 Judges
    • John Rubin, Executive Director, JP Morgan Private Bank
    • Charles J. Andres, Intellectual Property Associate, Wilson Sonsini Goodrich & Rosati (WSGR)
    • Raghav Bhargava, Associate, New Enterprise Associates (NEA)
    • Ethel Rubin, NIH Entrepreneur in Residence
    • Representative from AstraZeneca
PRIZES
Grand Prize provided by WSGR $10,000
Visibility in front of hundreds of attendees and prominent industry and venture capital judges
 
CRITERIA
Product, Technical Feasibility, Marketing/Strategy, Leadership Team, Financial/Projection
 

PRIZES

Grand Prize provided by WSGR $10,000

Visibility in front of hundreds of attendees and prominent industry and venture capital judges 

bhi updated logo 2017

Are you a start-up in Maryland, DC or Virginia seeking feedback on your biohealth business idea, pitch deck, or commercialization plan.  Sign up now to schedule your feedback session with BHI EIRs on Wednesday, February 27th.  (Next sessions scheduled for 3/20 and 5/22.)  Pre-registration is required; sign up here (“EIR resource”at BHI).  For questions/more information, contact This email address is being protected from spambots. You need JavaScript enabled to view it..

https___cdn.evbuc.com_images_55910079_290453431737_1_original.jpg

University of Maryland Institute for Bioscience & Biotechnology Research, 9600 Gudelsky Drive, Rockville, MD 20850

Register NOW:  https://tinyurl.com/BHISBIR2019

  • 8:00 a.m. – Networking and Registration
  • 8:30 a.m. – Welcome
  • 8:35 a.m. – SBIR Funding Opportunities at the National Institutes of Health
    • National Heart, Lung, and Blood Institute
    • National Institute on Aging
    • National Institute on Drug Abuse
    • National Cancer Institute  
  • 9:45 a.m. – Partnership Opportunities with NCI Frederick National Lab  
  • 10:00 a.m. – BREAK
  • 10:20 a.m. – SBIR Funding Opportunities with the National Science Foundation    
  • 11:00 a.m. – BREAK  
  • 11:15 a.m. – SBIR Funding Opportunities with USAMRC    
  • 11:45 a.m. –  Lunch  
  • 12:45 p.m. – (1:1 Room Set)  
  • 1:00 p.m. – Writing Your Specific Aims Page OR 1:1 Meetings* (available simultaneously)  
  • 1:30 p.m. – Writing Your Phase II Commercialization Plan OR 1:1 Meetings* (available simultaneously)  
  • 2:00 p.m. – Writing Your Specific Aims Page OR 1:1 Meetings* (available simultaneously)  
  • 2:30 p.m. –  Writing Your Phase II Commercialization Plan  OR 1:1 Meetings* (available simultaneously))  
  • 3:00 p.m. –  1:1 Meetings* (NIH only)  
  • 4:00 p.m. – Adjourn

Pre-Registration REQUIRED: RSVP by noon, February 26 at https://tinyurl.com/BHISBIR2019
No charge for entrepreneurs to attend • If seeking 1:1 meeting(s) please include organization(s) in RSVP.

rock-health-logo

Utilization of digital health services and technologies has been on the rise since we first began surveying the US adult population in 2015. Budding choices of wearables, apps, telemedicine, and other tech-enabled services make it easy for consumers to test out what it might be like to “go digital” for their health. In the first three years, our annual survey showed that tools for fitness and wellness represented a common (and low-risk) entry point for consumers to experiment with products that fit neatly into their already tech-enabled lifestyles. In the 2018 data that we examined for this report, we saw something different.

pitch-masters-logo

PitchMasters™, a workshop-style event for entrepreneurs preparing for their first institutional capital raise, held its 2019 Kick Off and Alumni Event on Jan. 30, 2019. Four emerging startup companies, Skipiit, Trove Therapeutics, Uplift and VERALOX Therapeutics, practiced their pitching skills and gained insights from experienced entrepreneurs, investors, industry influencers and fellow PitchMasters™ alumni.

brian-darmody-aurp-image

The Association of University Research Parks (AURP), a professional association of university-related research and science parks, announced the appointment of Brian Darmody, Associate Vice President of Corporate Engagement at the University of Maryland (UMD), as its new Chief Executive Officer (CEO). Additionally, the association has opened a new office at the UMD Discovery District in the Washington, DC area, to be known as ‘AURP HQ2.’ Mr. Darmody will immediately assume his new role as CEO at the new location. He will continue his role at UMD and plans to transition out of UMD over time.

704-qo-graph-image

When construction is completed this month, 704 QO will offer ready-to-occupy lab/office spaces for companies of all sizes. What really makes this new building stand out isn’t just the fully customizable individual lab units, but the suite of amenities that are tailored to the specific needs of emerging life science companies in the BioHealth Capital Region and the employees that work for them. 

iqvia-logo

IQVIA™ (NYSE:IQV) today announced the launch of IQVIA™ Biotech and its new approach to delivering tailored clinical and commercial solutions for small biotech and biopharma companies. This solutions suite, supported by more than 1,000 dedicated employees, will deliver simplified operating procedures, specialized teams, and services to provide a more agile way for these innovators to reach their drug development and commercialization milestones. From initial planning to trial design and implementation to market launch and commercialization, IQVIA Biotech delivers a transparent and streamlined process with a deep foundation in science.

astrazeneca-logo

AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for MEDI8897, an extended half-life respiratory syncytial virus (RSV) F monoclonal antibody (mAb) being developed for the prevention of lower respiratory tract infection (LRTI) caused by RSV.

vlp-therapeutics-logo

VLP Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for a clinical trial of the Company's VLPM01 malaria vaccine. The Phase I/IIa clinical trial will begin recruiting participants in February 2019, and is designed to assess the safety, immunogenicity and efficacy of the VLPM01 vaccine. The clinical trial will be conducted at the Walter Reed Army Institute of Research (WRAIR) in Silver Spring, MD.

sbir-sttr-seed-fund-logo

UMD IBBR - 9600 Gudelsky Drive, Rockville, MD 20850

February 28, 2019

Unique opportunity to meet 1:1 with multiple SBIR program managers and experts.

SCHEDULE

8:00 a.m. - 8:30 a.m. – Networking and Registration

8:30 a.m. - 12:00 p.m. – Program Overviews. Agencies represented:

NSF (National Science Foundation)

NIH NIA (National Institute on Aging)

NIH NCI (National Cancer Institute)

NIH NHLBI (National Heart, Lung, and Blood Institute)

NIH NIDA (National Institute on Drug Abuse)

US Army (invited)

12:00 p.m. - 1:00 p.m. – Networking Lunch

1:00 p.m. – 1:30 p.m. – Writing Specific Aims Page

1:30 – 2 p.m. – Writing Your Phase II Commercialization Program

2:00 – 2:30 p.m.  – Q&A with All speakers

2:30 - 4:00 p.m. - 1:1 – Meetings with Program Managers*

Pre-Registration REQUIRED: RSVP by noon, February 26 at https://tinyurl.com/BHISBIR2019

No charge for entrepreneurs to attend • If seeking 1:1 meeting(s) please include organization(s) in RSVP.

*You do not have to participate in 1:1 meetings. However, to do so, you must attend the overview session in person. 




getwell-network-logo

GetWellNetwork, the Precision Engagement health care company reaching 10 million patients annually, announced today a pivotal 2018 which will propel the company into 2019 as it continues to lead the evolution of patient engagement. The company furthered global expansion efforts, made several executive hires and acquired leading digital health company HealthLoop to catalyze growth in the ambulatory space.

dog-nose-smell-pixa

Lung cancer may not be the first thought that crosses the mind when talking about breathalyzer tests. But, what if lung cancer detection were as easy as breathing into a device? That is the goal of a group of researchers from the University of Exeter who have recently taken a new approach to e-nose technology integrated with multi-layered graphene for early detection of lung cancer.

Digital Health 100 LOGO 2018

Explore the 2018 Global Digital Health 100.

The Global Digital Health 100 is one of the HealthTech industries foremost technology awards programmes, celebrating innovation and entrepreneurship. It recognises and supports health technology companies that are demonstrating the greatest potential to change the way that healthcare is delivered.

rexahn-pharma-2019-logo

Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical-stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat, announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application No. 15/683,408, “Fluorocyclopentenylcytosine Methods of Use.” The patent application covers the use of RX-3117 in a broad range of tumor types that over-express UCK2, the enzyme that activates RX-3117. The company expects the patent to be issued within a few months from the notice of allowance and provide protection to 2036. 

biotalk finkel article image

Dr. Julia Finkel, Pediatric Anesthesiologist, Children's National Medical Center, joins Biotalk host Rich Bendis to discuss pain care management, the founding of startup AlgometRx, and the funding of this new companyDr. Julia Finkel, Pediatric Anesthesiologist, Children's National Medical Center, joins Biotalk host Rich Bendis to discuss pain care management, the founding of startup AlgometRx, and the funding of this new company.

Julia Finkel, M.D., is a pediatric anesthesiologist and director Pain Medicine Research and Development in the Sheikh Zayed Institute for Pediatric Surgical Innovation.

Dr. Finkel has extensive experience designing and conducting clinical trials relating to analgesics in children and has received both industry and federal funding of her research. Dr. Finkel is regularly invited to speak at national meetings on topics related to pediatric pain management.

Listen now on iTunes Google Play , and TuneIn

i270-corridor-lab-market-report-logo

The extremely active lab real estate market is a bell-weather for the upcoming hyper-competitive talent market. Based on the recent real estate transactions and related hiring forecasts, we estimate the range of new positions in the Maryland life sciences market to be between 1,150 to 2,300 new hires in 2019.

money-idea-invest-pixa

In the last decade, crowdfunding has become a popular way to finance all sorts of projects and products. Biotech is no exception, but many question whether the high risk and long term nature of investing in the biotech industry makes it a good fit for equity crowdfunding.

mcedc-logo

Maryland Tech Council (MTC) announced today that the Montgomery County Economic Development Corporation (MCEDC) will continue its partnership with and support of MTC's Venture Mentoring Services (VMS) program. MCEDC has funded the mentoring program for three years and will continue to support it in 2019-to further augment the growth of Montgomery County's target industries-technology and life sciences, while providing a key component to sustain economic growth in the County.

cerecor-2019-logo

Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments in rare and orphan diseases in pediatrics and neurology, announced today that it has moved its U.S. Corporate Offices to 540 Gaither Road Suite 400 located in Rockville, Maryland. The company had previously been based in Baltimore, Maryland.

crispr-therapeutics-logo

The highly touted gene-editing technology CRISPR is facing one of its first real-world tests. As many as 12 patients who live with the blood disorders sickle cell anemia or beta-thalassemia have started enrolling in a Europe-based clinical trial that may serve as an early indicator of whether gene editing will live up to the hype.